The role of the GH/IGF-I axis for cardiac function and structure

Hormone and Metabolic Research

Volumn 31, Issue 2-3, 1999, Pages 50-54

  Isgaard, Jörgen ^a   Tivesten, A ^a   Friberg, P ^a   Bengtsson, B A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiac; Growth hormone; Heart; Insulin like growth factor

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HEXARELIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR;

ARTICLE; CONGESTIVE HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE PRESSURE; HORMONE METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REGULATORY MECHANISM;

EID: 0032899473     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978698     Document Type: Article

References (62)

1. 1. Merola B, Cittadini A, Colao A, Longobardi S, Fazio S, Sabatini D, Saccà L, Lombardi G. Cardiac Structure and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993; 77: 1658-61
2. 2. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Saccà L, Bellastella A. Body composition, bone metabolism and heart structure and function in growth hormone (GH) deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-6
3. 3. Caidahl K, Edèn S, Bengtsson B-Å. Cardiovascular and renal effects of growth hormone. J Clin Endocrinol (Oxf) 1994; 40: 393-400
4. 4. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Saccà L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14
5. 5. Friberg P, Folkow B, Nordlander M. Structural adaptation of the rat left ventricle in response to changes in pressure and volume loads. Acta Physiol Scand 1985; 125: 67-79
6. 6. Schunkert H, Jahn L, Izumo S, Apstein CS, Lorell BH. Localization and regulation of c-fos and c-jun proto-oncogene induction by systolic wall stress in normal and hypertrophied rat hearts. Proc Natl Acad Sci USA 1991; 88: 11480-4
7. 7. Simpson PC. Role of proto-oncogenes in myocardial hypertrophy. Am J Cardiol 1988; 62: 136-96
8. 8. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 1993; 55: 55-75
9. 9. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van Bilsen M, O'Brien TX, Evans SM. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993; 55: 77-95
10. 10. Friberg P, Isgaard J, Wåhlander H, Wickmann A, Guron G, Adams MA. Cardiac hypertrophy and related growth processes: The role of insulin-like growth factor I. Blood Pressure 1995; 4 (Suppl. 2): 22-9
11. 11. Murphy LJ, Bell GI, Duckworth L, Friesen G. Identification, characterization and regulation of a rat complimentary deoxyribonucleic acid which encodes insulin-like growth factor I. Endocrinology 1987; 121: 684-91
12. 12. Isgaard J, Nilsson A, Vikman K, Isaksson OGP. Growth hormone regulates the level of insulin-like growth factor I in rat skeletal muscle. J Endocrinol 1989; 120: 107-12
13. 13. D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentration of somatomedin-C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984; 81: 935-9
14. 14. Han VKM, D'Ercole AJ, Lund KP. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 1987; 236: 193-7
15. 15. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese VM. Induction of myocardial insulin-like growth factor I gene expression in left ventricular hypertrophy. Circulation 1994; 89: 799-809
16. 16. Wåhlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992; 19: 25-32
17. 17. Guron G, Friberg P, Wickman A, Brantsing C, Gabrielsson B, Isgaard J. Cardiac insulin-like growth factor I and growth hormone receptor expression in renal hypertension. Hypertension 1996; 27 (part 2): 636-42
18. 18. Mirsky J. Elastic properties of the myocardium: a quantitative approach with physiological and clinical applications. In: Handbook of Physiology. American Physiological Society 1979; I, 14, 2: 497-531
19. 19. Isgaard J, Wåhlander H, Adams MA, Friberg P. Increased expression of growth hormone receptor mRNA and insulin-like growth factor I mRNA in volume overloaded hearts. Hypertension 1994; 23: 884-8
20. 20. Russell-Jones DL, Leach RM, Ward JPT, Thomas CR. Insulin-like growth factor-I gene expression is increased in the right ventricle hypertrophy induced by chronic hypoxia in the rat. J Endocrinol 1993; 10: 99-102
21. 21. Reiss K, Meggs LG, Li P, Olivetti G, Capasso JM, Anversa P. Upregulation of IGF-I IGF-I receptor and late growth related genes in ventricular myocytes acutely after infarction in rats. J Cell Physiol 1994; 158: 160-8
22. 22. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Card Vasc Res 1995; 30: 825-34
23. 23. Chen Y, Arner A, Bornfeldt KE, Uvelius B, Arnqvist HJ. Development of smooth muscle cell hypertrophy is closely associated with increased gene expression of insulin-like growth factor binding protein-2 and -4. Growth Regulation 1995; 5: 45-52
24. 24. Kluge A, Zimmermann R, Weihrauch , Mohri M, Sack S, Schaper J, Schaper W. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart. Cardiovasc Res 1997; 33: 324-31
25. 25. Mathews LS, Engberg B, Norstedt G. Regulation of rat GH receptor gene expression. J Biol Chem 1989; 264: 9905-10
26. 26. Ymer SI, Herington AC. Developmental expression of the growth hormone receptor gene in rabbit tissues. Mol Cell Endocrinol 1992; 83: 39-49
27. 27. Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation. Circulation 1996; 93: 800-9
28. 28. Yang R, Bunting S, Gillet N, Clark R, Jin H. Growth improves cardiac performance in experimental performance. Circulation 1995; 92: 262-7
29. 29. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross Jr J. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-27
30. 30. Isgaard J, Kujacic V, Jennische E, Jolmäng A, Sun XY, Hedner T, Hjalmarson A, Bengtsson B-A. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997; 27: 517-25
31. 31. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 1995; 26: 420-5
32. 32. Shen YT, Wiedmann RT, Lynch JJ, Grossman W, Johnson RG. GH replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction. Am J Physiol 1996; 271: H1721-H1727
33. 33. Cittadini A, Grossman J, Napoli R, Katz S, Strömer H, Smith R, Morgan JP, Douglas P. Growth hormone attenuates early ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am College Cardiol 1997; 29: 1109-16
34. 34. Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sönksen PH. Cardiac failure responding to growth hormone. Lancet 1989; 1: 838-9
35. 35. Frustaci A, Perrone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992; 97: 503-11
36. 36. O'Driscoll JG, Green DJ, Ireland M, Kerr D, Larbalestier RI. Treatment of endstage cardiac failure with growth hormone. Lancet 1997; 349: 1068
37. 37. Volterrani M, Desenzani P, Lorusso R, d'Aloia A, Manelli F, Giustina A. Hemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997; 349: 1067-8
38. 38. Beer N, Tortoledo F, Beer R, Pinedo M. Beneficial effects of growth hormone in patients with congestive heart failure. Circulation (abstract 2920) 1997; 96 (Suppl. 1): I-521
39. 39. Turner H, Wass JAH. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 335: 672
40. 40. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 335: 672-3
41. 41. Isgaard J, Bergh C-H, Caidahl K, Lomsky M, Hjalmatson A, Bengtsson B-Å. A placebo controlled study of growth hormone in patients with congestive heart failure. Eur Heart J, 1998; 19: 1704-11
42. 42. Mayoux E, Ventura-Clapier R, Timsit J, Béhar-Cohen F, Hoffman C, Mercadier J-J. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res 1993; 72: 57-64
43. 2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res 1996; 79: 227-36
44. 44. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichini M, Koike A, Nogami A, Marumo F. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-21
45. 45. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle I-actin of adult cardiomyocytes. Proc Natl Acad Ski USA 1994; 91: 1686-90
46. 46. Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 1996; 163/164: 223-9
47. 47. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997; 95: 320-3
48. 48. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335: 1182-9
49. 49. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43
50. 50. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56
51. 51. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74: 86-1 07
52. 52. Buerke M, Mohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci (USA) 1995; 92: 8031 -5
53. 53. Buerke M, Prufer D, Ibe W, Ekincí O, Dahm M, Oelert H, Meyer J. Human growth hormone exerts cardioprotective effects in murine reperfusion injury. Abstract #2116, 70th Scientific Session of the American Heart Association. Orlando: November 19 97
54. 54. Howard AD, Feighner SD, Cully DF, Arena JP, Libeartor PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong S-S, Chaung L-Y, Elbrecht A, Dashkevicz M, Heavens R, Ribgy M, Sirinathsinghji DJS, Dean DC, Melillo DC, Patchett AA, Nargund R, Griffin PR, De Martino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974 -7
55. 55. McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van der Ploeg LHT, Howard AD. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 1997; 11: 415-23
56. 56. Ong H, McNicoll E, Escher E, Collu R, Deghenghi R, Locatelli V, Ghigo E, Muccioli G, Boghen M, Nilsson M. Identification of a pituitary growth hormone releasing peptide (GHRP) receptor subtype by photoaffinity labeling. Endocrinology 1998; 139: 432 -5
57. 57. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol 1995; 43: 631 -5
58. 58. Cella SG, Cerri CG, Daniel S, Sibila V, Rigamonti A, Cattaneo L, Deghenghi R, Müller EE. Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotrophic axis, muscle morphology and bone metabolism. J Geront A Biol Sci Med Sci 1996; 51: B439-B4 47
59. 59. Tivesten Å, Bollano E, Kujacic V, Caidahl K, Sun XY, Hedner T, Hjalmarson Å, Isgaard J. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. 47th Annual Scientific Session. American College of Cardiology, Atlanta, GA: Abstract #230493, 19 98
60. 60. De Gennaro Colonna VG, Rossini M, Bernareggi M, Müller EE, Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone deficient rats. Protection by hexarelin. Eur J Pharm 1997; 334: 201 -7
61. 61. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Boghen MF, Deghenghi R, France A, Ghigo E. The acute administration of hexarelin, a synthetic GH releasing peptide but not growth hormone increases LVEF in normal man. Abstract #2019, 70th Scientific Session of the American Heart Association. Orlando: November 19 97
62. 62. Ong H, Bodart V, McNicoll N, Lamontagne D, Bouchard JF. Binding sites for growth hormone releasing peptide. GH and IGF Res 1998; 8 (Suppl. B): 137-40